ATAI Life Sciences Shareholders Approve Combination With Beckley Psytech

Reuters11-05

<a href="https://laohu8.com/S/ATAI">ATAI Life</a> Sciences Shareholders Approve Combination With Beckley Psytech

Atai Life Sciences and Beckley Psytech have completed their strategic combination to form AtaiBeckley, a biopharmaceutical company focused on developing transformative mental health therapies. The transaction was approved by approximately 98% of atai shareholders at an extraordinary general meeting. The combined company features an industry-leading pipeline, including BPL-003 (mebufotenin benzoate nasal spray) as a Phase 3-ready asset, as well as Phase 2 assets VLS-01 (DMT buccal film) and EMP-01 (oral R-MDMA). Beckley shareholders, certain equity award holders, and consultants will receive approximately 105 million new AtaiBeckley shares, representing about 28% of the combined company. AtaiBeckley reports a strong cash position, with sufficient funding to support operations into 2029, including through anticipated topline data from the first Phase 3 trial of BPL-003.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ATAI Life Sciences NV published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9569295-en) on November 05, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2581721597?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-05 20:02","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2581721597","market":"nz","top_or_hot":-1,"title":"ATAI Life Sciences Shareholders Approve Combination With Beckley Psytech","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/ATAI\">ATAI Life</a> Sciences Shareholders Approve Combination With Beckley Psytech\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Atai Life Sciences and Beckley Psytech have completed their strategic combination to form AtaiBeckley, a biopharmaceutical company focused on developing transformative mental health therapies. The transaction was approved by approximately 98% of atai shareholders at an extraordinary general meeting. The combined company features an industry-leading pipeline, including BPL-003 (mebufotenin benzoate nasal spray) as a Phase 3-ready asset, as well as Phase 2 assets VLS-01 (DMT buccal film) and EMP-01 (oral R-MDMA). Beckley shareholders, certain equity award holders, and consultants will receive approximately 105 million new AtaiBeckley shares, representing about 28% of the combined company. AtaiBeckley reports a strong cash position, with sufficient funding to support operations into 2029, including through anticipated topline data from the first Phase 3 trial of BPL-003.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ATAI Life Sciences NV published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9569295-en) on November 05, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>ATAI Life Sciences Shareholders Approve Combination With Beckley Psytech</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nATAI Life Sciences Shareholders Approve Combination With Beckley Psytech\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-11-05 20:02</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/ATAI\">ATAI Life</a> Sciences Shareholders Approve Combination With Beckley Psytech\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Atai Life Sciences and Beckley Psytech have completed their strategic combination to form AtaiBeckley, a biopharmaceutical company focused on developing transformative mental health therapies. The transaction was approved by approximately 98% of atai shareholders at an extraordinary general meeting. The combined company features an industry-leading pipeline, including BPL-003 (mebufotenin benzoate nasal spray) as a Phase 3-ready asset, as well as Phase 2 assets VLS-01 (DMT buccal film) and EMP-01 (oral R-MDMA). Beckley shareholders, certain equity award holders, and consultants will receive approximately 105 million new AtaiBeckley shares, representing about 28% of the combined company. AtaiBeckley reports a strong cash position, with sufficient funding to support operations into 2029, including through anticipated topline data from the first Phase 3 trial of BPL-003.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ATAI Life Sciences NV published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9569295-en) on November 05, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4585","symbol_name":"ETF&股票定投概念","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251105:nNDL7JQN9c:1","article_id":"2581721597","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2581721597","pubTimestamp":1762344163,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Atai Life Sciences and Beckley Psytech have completed their strategic combination to form AtaiBeckley, a biopharmaceutical company focused on developing transformative mental health therapies. The transaction was approved by approximately 98% of atai shareholders at an extraordinary general meeting. The combined company features an industry-leading pipeline, including BPL-003  as a Phase 3-ready asset, as well as Phase 2 assets VLS-01  and EMP-01 . Beckley shareholders, certain equity award holders, and consultants will receive approximately 105 million new AtaiBeckley shares, representing about 28% of the combined company. AtaiBeckley reports a strong cash position, with sufficient funding to support operations into 2029, including through anticipated topline data from the first Phase 3 trial of BPL-003.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generat","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4585":"ETF&股票定投概念","LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD","LU0314104364.USD":"MANULIFE GF AMERICAN GROWTH \"AA\" (USD) INC","IE00B3QW5Z07.USD":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC","BK4007":"制药","IE00BKPKM429.USD":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC","LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H","LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD","ATAI":"Atai Beckley Inc","IE00BGHQF748.EUR":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC","NDAQ":"纳斯达克OMX交易所","BK4588":"碎股","BK4539":"次新股","BK4112":"金融交易所和数据","IE00B64PRP62.GBP":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC"},"translate_title":"ATAI Life Sciences股东批准与Beckley Psytech合并","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NDAQ":0.9,"ATAI":0.9},"content_text":"ATAI Life Sciences Shareholders Approve Combination With Beckley Psytech\n    \n\n        Atai Life Sciences and Beckley Psytech have completed their strategic combination to form AtaiBeckley, a biopharmaceutical company focused on developing transformative mental health therapies. The transaction was approved by approximately 98% of atai shareholders at an extraordinary general meeting. The combined company features an industry-leading pipeline, including BPL-003 (mebufotenin benzoate nasal spray) as a Phase 3-ready asset, as well as Phase 2 assets VLS-01 (DMT buccal film) and EMP-01 (oral R-MDMA). Beckley shareholders, certain equity award holders, and consultants will receive approximately 105 million new AtaiBeckley shares, representing about 28% of the combined company. AtaiBeckley reports a strong cash position, with sufficient funding to support operations into 2029, including through anticipated topline data from the first Phase 3 trial of BPL-003.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ATAI Life Sciences NV published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9569295-en) on November 05, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.9","shortVersion":"4.35.9","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2581721597","isCrawlerRequest":true}